Dynavax Technologies Corp. (NASDAQ:DVAX) has been given a $4.00 target price by analysts at RBC Capital Markets in a note issued to investors on Monday. The firm currently has a a “hold” rating on the biopharmaceutical company’s stock. RBC Capital Markets’ price objective would suggest a potential downside of 15.79% from the stock’s current price.

DVAX has been the topic of several other reports. Zacks Investment Research raised shares of Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research report on Monday, September 5th. Cowen and Company reissued an “outperform” rating and issued a $45.00 price objective on shares of Dynavax Technologies Corp. in a research report on Tuesday, September 6th. S&P Equity Research upped their price target on shares of Dynavax Technologies Corp. from $11.28 to $16.01 in a research note on Friday, September 2nd. Finally, William Blair restated a “buy” rating and issued a $45.00 price target on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $24.14.

Analyst Recommendations for Dynavax Technologies Corp. (NASDAQ:DVAX)

Dynavax Technologies Corp. (NASDAQ:DVAX) opened at 4.75 on Monday. The company’s 50-day moving average is $10.15 and its 200 day moving average is $13.64. The company’s market capitalization is $183.00 million. Dynavax Technologies Corp. has a one year low of $3.20 and a one year high of $29.86.

Dynavax Technologies Corp. (NASDAQ:DVAX) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.15. The company earned $0.20 million during the quarter, compared to the consensus estimate of $2.44 million. Dynavax Technologies Corp. had a negative net margin of 2,650.25% and a negative return on equity of 78.57%. Dynavax Technologies Corp.’s revenue for the quarter was down 83.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.82) earnings per share. Analysts predict that Dynavax Technologies Corp. will post ($3.21) EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in DVAX. Quantbot Technologies LP purchased a new stake in shares of Dynavax Technologies Corp. during the third quarter worth about $102,000. Rathbone Brothers plc purchased a new stake in shares of Dynavax Technologies Corp. during the third quarter worth about $105,000. Meeder Asset Management Inc. purchased a new stake in shares of Dynavax Technologies Corp. during the second quarter worth about $107,000. Two Sigma Securities LLC purchased a new stake in shares of Dynavax Technologies Corp. during the third quarter worth about $115,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Dynavax Technologies Corp. during the third quarter worth about $125,000. Institutional investors and hedge funds own 85.18% of the company’s stock.

About Dynavax Technologies Corp.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Receive News & Stock Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related stocks with our FREE daily email newsletter.